Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
We are currently selecting our lead IL-18 variant on the basis of potency for the IL-18 receptor, optimal pharmacokinetic profile and in vivo efficacy for inhibiting tumour growth. American Association for Cancer Research; 2006 [cited 2023 Jun 6]. Ultimately, our goal is for this approach to yield an enhanced cancer fighting response.
98 
Let's personalize your content